- Home
- QURE
QURE
uniQure N.V.
as of 12-26-2025 4:00pm EST
$24.81
$0.67
-2.64%
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | 1.9B | IPO Year: | 2007 |
| Target Price: | $58.55 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.76 - $71.50 | Next Earning Date: | 11-10-2025 |
| Revenue: | $15,751,000 | Revenue Growth: | -44.90% |
| Revenue Growth (this year): | -38.4% | Revenue Growth (next year): | 153.45% |
AI-Powered QURE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 83.44%
83.44%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of uniQure N.V. (QURE)
Gut Robert
Sell
Director
QURE Nov 6, 2025
Avg Cost/Share
$27.26
Shares
31,434
Total Value
$856,881.00
Owned After
55,739
Latest uniQure N.V. News
QURE Breaking Stock News: Dive into QURE Ticker-Specific Updates for Smart Investing
Compare QURE vs Leading Stocks
See how QURE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.